33 Consistent with these results, we recently demonstrated that daily treatment with Resolvin-D1 (RvD1), an inflammation–resolution promoting autacoid, can attenuate Ca2+-handling abnormalities by normalizing Cacna1c, Ryr2, and Scn5a expression in AF models of pressure-overload-induced right heart disease, and myocardial infarction.12,34. The gene discussed is RYR2; the disease is atrial fibrillation.